Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Overig advies 26/06/2021 06:35
. Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1
. New ready-to-dilute format and 1,000 mg strength option helps avoid unnecessary handling steps to reduce associated contamination risks and patient waiting times2
. The Pemetrexed launch will expand the Sandoz hospital portfolio in key European markets, strengthening access to treatment options for patients

Basel, June 25, 2021 — Sandoz today announced the launch of generic oncology treatment Pemetrexed in 11 countries across Europe, including Germany, Switzerland, Netherlands, and Spain.

Pemetrexed, as a monotherapy or in combination with cisplatin, is indicated for first-line, second-line and maintenance treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology, and for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.3

Globally, 1.8 million people died from lung cancer in 2020 including over 26,000 deaths from mesothelioma, and approximately 2.2 million new cases of lung cancer including 31,000 new cases of mesothelioma were diagnosed.4 NSCLC is the most prevalent form of the disease, affecting approximately 85% of those diagnosed with lung cancer.5,6

“At Sandoz, we are committed to using our expertise in product development to enable us to deliver high quality, innovative products that address the needs of patients and healthcare professionals,” said Rebecca Guntern, Head of Sandoz Region Europe. “By providing Pemetrexed in a ready-to-dilute format and in an additional, higher-strength dosage, we believe that this treatment option will not only be more cost-effective for payers, but patients and physicians will also be able to benefit from the reduced preparation steps required.”

Pemetrexed is a multi-targeted antifolate anti-cancer agent that disrupts crucial folate-dependent metabolic processes essential for cell replication. It inhibits folate-dependent enzymes critical to the de-novo biosynthesis of nucleotides leading to the disruption of DNA replication. Patients receive the treatment via a 10-minute intravenous infusion in a hospital setting.3

Further launches across Europe are expected throughout the second half of 2021.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward- etc.

References

Narjust D., Rafael S., Julian R. Mayo Clin Proc. 2019; 94(8):1623-1640. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Accessible at: https://pubmed.ncbi.nlm.nih.gov/31378236/
Favier B, et al. The time-saving and economic advantages of using oxaliplatin concentrated solution for infusion versus oxaliplatin lyophilized powder for infusion. EJHP Practice. 2007; 13(1): 28-34.
Alimta Summary of Product Characteristics. Accessible at: https://www.ema.europa.eu/en/documents/product-information/alimta-epar-product-information_en.pdf (Accessed May 2021)
Hyuna Sung et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancer in 185 Countries. CA Caner J Clin. 2021; 0: 1-41
Navada S, et al. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database [abstract 7082]. J Clin Oncol. 2006;24(18S) suppl:384S.
Tan WW, et al. Non-Small Cell Lung Cancer (NSCLC). Medscape. Updated March 10 2021. Available at: https://emedicine.medscape.com/article/279960-overview (Accessed June 2021)
# # #



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL